TY - JOUR
T1 - Chemoprevention of colorectal cancer
T2 - Problems, progress, and prospects
AU - Viner, Jaye L.
AU - Umar, Asad
AU - Hawk, Ernest T.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002/12
Y1 - 2002/12
N2 - Chemoprevention holds great promise as a complement to traditional CRC screening and treatment. Effective chemopreventive agents might improve patient outcomes by reducing the number of missed lesions, the morbidity associated with their identification and treatment, and their malignant potential. In addition, chemoprevention may reduce neoplastic potential simultaneously in several organs and improve clinical outcomes for persons at risk for cancers at multiple sites (eg, colorectal and extracolonic cancers in HNPCC cohorts). Complex molecular circuits underlie the disease mosaic that is associated with aging. Several of these diseases share common mechanisms against which preventive interventions appear to be effective, such as NSAIDs for colorectal neoplasia and neurodegenerative disease, and statins for cardiovascular disease and colorectal neoplasia. Understanding these mechanisms and effects could raise prevention science to an entirely new level. The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6).
AB - Chemoprevention holds great promise as a complement to traditional CRC screening and treatment. Effective chemopreventive agents might improve patient outcomes by reducing the number of missed lesions, the morbidity associated with their identification and treatment, and their malignant potential. In addition, chemoprevention may reduce neoplastic potential simultaneously in several organs and improve clinical outcomes for persons at risk for cancers at multiple sites (eg, colorectal and extracolonic cancers in HNPCC cohorts). Complex molecular circuits underlie the disease mosaic that is associated with aging. Several of these diseases share common mechanisms against which preventive interventions appear to be effective, such as NSAIDs for colorectal neoplasia and neurodegenerative disease, and statins for cardiovascular disease and colorectal neoplasia. Understanding these mechanisms and effects could raise prevention science to an entirely new level. The number of trials that are investigating chemopreventives against CR neoplasia is relatively small; if these agents live up to a fraction of their promise, the public health impact may be great (see Table 6).
UR - http://www.scopus.com/inward/record.url?scp=0036896978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036896978&partnerID=8YFLogxK
U2 - 10.1016/S0889-8553(02)00055-9
DO - 10.1016/S0889-8553(02)00055-9
M3 - Review article
C2 - 12489273
AN - SCOPUS:0036896978
SN - 0889-8553
VL - 31
SP - 971
EP - 999
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 4
ER -